10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
Sarepta Therapeutics Inc. (SRPT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 2,865,100 | $348,367,509 | +12% | 1.76% |
| 2. | VenBio Select Advisor Kurt Von Emster | 2,555,555 | $310,729,932 | 4.39% | |
| 3. | Casdin Capital Eli Casdin | 1,073,500 | $130,526,865 | 8.68% | |
| 4. | OrbiMed Advisors Samuel Isaly | 963,400 | $117,139,806 | +1% | 2.4% |
| 5. | Alkeon Capital Management Panayotis Takis Sparaggis | 853,845 | $103,819,013 | +35% | 0.21% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $134.66 | 5,648 | 284,034 | 2024-08-16 | Filing | ||
| $134.06 | 18,284 | 278,386 | 2024-08-16 | Filing | ||
| $133.07 | 13,106 | 260,102 | 2024-08-16 | Filing | ||
| $78.81 | 40,000 | Director | 140,000 | 2023-11-03 | Filing | |
| $78.81 | 10,000 | Director | 10,000 | 2023-11-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.64 | 2,491 | 27,812 | 2025-03-12 | Filing | ||
| $124.84 | 10,500 | 22,840 | 2024-12-12 | Filing | ||
| $125.55 | 1,636 | 5,880 | 2024-12-05 | Filing | ||
| $137.36 | 5,985 | 33,946 | 2024-08-30 | Filing | ||
| $164.52 | 2,549 | 17,129 | 2024-06-25 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,191,986 | $1,360,833,548 | 0.02% | |
| 2. | 9,085,456 | $1,104,700,596 | 0.01% | |
| 3. | 8,697,137 | $1,057,482,090 | 0.19% | |
| 4. | 4,328,323 | $526,204,179 | 0.26% | |
| 5. | 4,069,864 | $494,854,764 | 0.01% |
News See All
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2024 Earnings Call Transcript
Operator: Good afternoon. And welcome to the Sarepta Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call. As a reminder, today’s program is being recorded.
15 Stocks That Will Go to The Moon According to Analysts
While stocks initially fell based on worries regarding Trump tariffs on America’s major trading partners, major indexes recovered from their initial losses as the President delayed tariffs on Mexico...
15 Best Fast Growth Stocks To Buy Right Now
In the fourth quarter of 2024, the US Gross Domestic Product (GDP) expanded at an annual rate of 2.3%, slightly below market expectations of 2.7% and a deceleration from the 3.1% growth observed in the...
12 Best Healthcare Stocks to Buy According to Analysts
McKinsey reported that, since 2019, the US healthcare industry witnessed significant financial pressure.
Jim Cramer’s Lightning Rounds: 9 Stocks in Focus
Jim Cramer, the host of Mad Money, recently expressed his concerns about the uncertain economic outlook for 2025, particularly in relation to corporate earnings and the stock market's expectations for...
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory
We came across a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on SRPT.
10 Best Gene Therapy Stocks to Buy Right Now
Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or prevent disease.
10 Best Performing Biotech Stocks in 2024
The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and government assistance.
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory
We came across a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) on Substack by Two Natural Capital. In this article, we will summarize the bulls’ thesis on SRPT. Sarepta Therapeutics, Inc.